Deals
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Employees of Juno received a surprise in their Monday morning emails.
The latest acquisition makes it the highest amount paid for a flex R&D building in Los Angeles County.
The year is already off to a good start with mergers and acquisitions in the biopharma industry.
Sinocare of Changsha may bid as much as $4B to acquire J&J’s diabetes medical device subsidiaries
Most investors and analysts are expecting 2018 to be a big year for mergers and acquisitions.
The deal has Sanofi paying $105 per share in cash.
The announcement sent shares of Juno soaring more than 27 percent in pre-market trading to $86.26.
A look at whether the new tax reform will really spur a M&A spending spree for drugmakers.
The company believes its ultrasensitive immunoassay technology is well-suited to pharma research.
Immune Design is a clinical-stage immunotherapy company.